The innovators working to make in vivo cell therapy a reality
As in vivo cell therapies enter clinical trials, suppliers tackle the technical and logistical barriers to commercial viability.
Cancer
Dewpoint receives FDA orphan drug designation for DPTX3186
FDA approves Lilly’s Inluriyo to treat advanced breast cancer
FDA to priority-review Daiichi Sankyo and AZ’s Enhertu sBLA
Akeso gains NMPA approval for cadonilimab to treat cervical cancer
ASCO25: J&J’s trispecific antibody shows 100% response in Phase I multiple myeloma study
Epsilogen acquires TigaTx to expand pan-isotope cancer antibody pipeline
NICE green lights two blood cancer therapies for NHS use
